ICU Medical, Inc. (NASDAQ:ICUI) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• ICU Medical, Inc. has received a consensus recommendation of "Buy" from analysts, with an average 12-month price target of $179.00 based on coverage from five research firms.
• CEO Vivek Jain acquired 21,929 shares of ICU Medical at an average price of $112.84, increasing his stake by over 20%, while COO Christian B. Voigtlander sold 4,985 shares at an average price of $128.50.
• In its latest earnings report, ICU Medical reported an EPS of $2.10, surpassing estimates, though revenue was down 8.0% year-over-year at $543.57 million.

Shares of ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) have received an average recommendation of "Buy" from the five research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $179.00.

A number of analysts have commented on the company. Piper Sandler assumed coverage on ICU Medical in a report on Friday. They issued an "overweight" rating and a $145.00 target price for the company. Raymond James Financial lowered their target price on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a research report on Friday, August 8th. Wall Street Zen cut ICU Medical from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, KeyCorp reduced their target price on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a report on Monday, April 21st.

Insider Activity at ICU Medical

In other ICU Medical news, CEO Vivek Jain acquired 21,929 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was bought at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the completion of the transaction, the chief executive officer owned 130,149 shares of the company's stock, valued at approximately $14,686,013.16. The trade was a 20.26% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Christian B. Voigtlander sold 4,985 shares of the firm's stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $128.50, for a total value of $640,572.50. Following the transaction, the chief operating officer owned 6,088 shares of the company's stock, valued at approximately $782,308. This represents a 45.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,044 shares of company stock valued at $2,783,128. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ICU Medical

Several institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 153 shares during the period. SG Americas Securities LLC bought a new position in shares of ICU Medical in the first quarter valued at approximately $859,000. Vontobel Holding Ltd. bought a new stake in ICU Medical during the first quarter worth approximately $235,000. Invesco Ltd. lifted its position in ICU Medical by 12.4% in the 4th quarter. Invesco Ltd. now owns 113,153 shares of the medical instruments supplier's stock worth $17,558,000 after buying an additional 12,489 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in shares of ICU Medical by 88.8% during the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.

ICU Medical Stock Performance

NASDAQ:ICUI opened at $111.90 on Friday. ICU Medical has a 52-week low of $107.00 and a 52-week high of $196.26. The business's fifty day moving average is $128.45 and its 200 day moving average is $138.76. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. The firm has a market cap of $2.76 billion, a price-to-earnings ratio of -73.62 and a beta of 0.88.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, beating analysts' consensus estimates of $1.44 by $0.66. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%. The business had revenue of $543.57 million during the quarter, compared to analyst estimates of $543.33 million. During the same quarter in the prior year, the company posted $1.56 EPS. ICU Medical's quarterly revenue was down 8.0% compared to the same quarter last year. Research analysts predict that ICU Medical will post 4.11 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.